Jaimie Heldstab

545 total citations
8 papers, 63 citations indexed

About

Jaimie Heldstab is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Jaimie Heldstab has authored 8 papers receiving a total of 63 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Cancer Research and 3 papers in Molecular Biology. Recurrent topics in Jaimie Heldstab's work include Cancer Genomics and Diagnostics (3 papers), BRCA gene mutations in cancer (2 papers) and Cancer Cells and Metastasis (2 papers). Jaimie Heldstab is often cited by papers focused on Cancer Genomics and Diagnostics (3 papers), BRCA gene mutations in cancer (2 papers) and Cancer Cells and Metastasis (2 papers). Jaimie Heldstab collaborates with scholars based in United States. Jaimie Heldstab's co-authors include Andrew K. Godwin, Anne O’Dea, Qamar J. Khan, Bruce F. Kimler, Priyanka Sharma, Manana Elia, Rachel Yoder, Harsh B. Pathak, Joshua M. Staley and Kelsey Schwensen and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and npj Breast Cancer.

In The Last Decade

Jaimie Heldstab

7 papers receiving 63 citations

Peers

Jaimie Heldstab

ONCOL

MB

CR

PRM

PFM

Jesús Miranda Spain

Filomena Di Giacomo United States

Erik Tilch Germany

Geoffrey Fell United States

Samuel M. Niman United States

Bomiao Hu United States

Jim Cregg Netherlands

Madoka Kawaguchi Japan

Cornelia Kolberg-Liedtke Germany

Sébastien Armanet France

Jesús Miranda Spain

Jaimie Heldstab

22 ×0.6

ONCOL

21 ×0.6

MB

26 ×1.0

CR

23 ×1.0

PRM

10 ×1.7

PFM

Citations per year, relative to Jaimie Heldstab Jaimie Heldstab (= 1×) peers Jesús Miranda

Countries citing papers authored by Jaimie Heldstab

Since Specialization

Citations

This map shows the geographic impact of Jaimie Heldstab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaimie Heldstab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaimie Heldstab more than expected).

Fields of papers citing papers by Jaimie Heldstab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaimie Heldstab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaimie Heldstab. The network helps show where Jaimie Heldstab may publish in the future.

Co-authorship network of co-authors of Jaimie Heldstab

This figure shows the co-authorship network connecting the top 25 collaborators of Jaimie Heldstab. A scholar is included among the top collaborators of Jaimie Heldstab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaimie Heldstab. Jaimie Heldstab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Sharma, Priyanka, Jaimie Heldstab, Rachel Yoder, et al.. (2025). Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology. 43(16_suppl). 1094–1094.

2.

Stecklein, Shane R., Bruce F. Kimler, Rachel Yoder, et al.. (2023). ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. npj Breast Cancer. 9(1). 10–10. 16 indexed citations

3.

Stecklein, Shane R., Devin C. Koestler, Nanda Kumar Yellapu, et al.. (2023). Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).. Journal of Clinical Oncology. 41(16_suppl). 578–578. 3 indexed citations

4.

Sharma, Priyanka, Shane R. Stecklein, Bruce F. Kimler, et al.. (2022). Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease. Cancer Research. 82(4_Supplement). P2–1. 2 indexed citations

5.

Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2021). Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). 1076–1076. 16 indexed citations

6.

Larson, Kelsey E., Yen Y. Wang, Rachel Yoder, et al.. (2019). Impact of Germline <i>BRCA</i> Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer. 7(4). 81–81. 1 indexed citations

7.

Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2018). Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1018–1018. 21 indexed citations

8.

Heldstab, Jaimie, Ossama Tawfik, Ryan Ash, et al.. (2017). Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis. JCO Precision Oncology. 1(1). 1–6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact